Sign Out
5-Alpha Reductase Inhibitor.
Pharmacology: Pharmacodynamics: Finasteride is a competitive inhibitor of human 5α-reductase, an intracellular enzyme which metabolizes testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor.
Pharmacokinetics: Finasteride is absorbed following oral administration, and peak plasma concentrations are achieved in 1 to 2 hours. The mean terminal half-life is about 6 hours in patients under 60 years of age but may be prolonged to about 8 hours in those 70 years of age or older.
Continue with Google